CO101 Multiple Myeloma (MM) Refractory to Lenalidomide: A Systematic Literature Review (SLR) of Randomised Controlled Trials (RCTs)

Lenalidomide is increasingly used in early lines of therapy for patients with MM. Patients treated with lenalidomide, especially in maintenance settings, often experience relapse and become refractory. RCTs in second line and beyond (2L+) feature patients with varying lenalidomide exposure resulting in variable outcomes. Evaluation of 2L+ RCTs focusing on first-line lenalidomide exposure and subsequent impact on outcomes is valuable; understanding the evidence supporting therapies and associated outcomes in 2L+ lenalidomide-refractory patients is vital.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research